Wednesday, 19 July 2017 14:18

OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

Written by 
Rate this item
(0 votes)
Read 387 times